
Unaudited

Registered Number 14164426
(Registered in England & Wales)
Brera Life Sciences Consultancy Trading Limited
Unaudited Report and Accounts
For the period ended 30 September 2022



Brera Life Sciences Consultancy Trading Limited

Company Information

Directors:

Edward William Mole CTC Directorships Ltd

Secretary:

Corporate Trading Companies Secretaries Limited

Registered Office:

6th Floor 338 Euston Road London NW1 3BG

Business Address

6th Floor 338 Euston Road London NW1 3BG

Bankers

The Royal Bank of Scotland

Brera Life Sciences Consultancy Trading Limited

Registered Number 14164426

Directors' Report

The directors present their report and accounts for the period ended 30 September 2022.

Results and Dividends

The profit for the period after taxation amounted to £2,086.

There were no dividends paid or proposed during the period.

Principal Activity

The company participates in operating partnerships which trade in the lending sector.

Directors

The following directors served during the period:

Appointed

Edward William Mole 10/06/2022 CTC Directorships Ltd 10/06/2022

The directors had no interests in the ordinary shares of the company as at 30 September 2022 or at the date of their appointment.

Directors' Report (Continued)

Directors' Responsibilities

The Directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the Directors to prepare financial statements for each financial year. Under that law the Directors have elected to prepare the financial statements in accordance with FRS 102 Section 1A - small entities. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period. In preparing these financial statements, the directors are required to:

- · select suitable accounting policies and then apply them consistently;
- · make judgements and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Directors' Report has been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

This report was approved by the Board and authorised for issue on 28 April 2023.

And signed on their behalf by:

Edward Mole

On behalf of CTC Directorships Ltd

Director

Statement of Total Comprehensive Income for the period ended 30 September 2022

	Period to 30 September 2022
	£
Share of net income or (loss) from operating partnerships	2,575
Administration costs	-
Operating Profit	2,575
Interest - receivable	-
Profit on ordinary activities	
before taxation	2,575
Taxation	(489)
Retained Profit for the financial period	2,086

All results relate to continuing activities.

All recognised gains and losses are included in the profit and loss account.

The notes to the accounts form part of these financial statements.

Statement of Financial Position as at 30 September 2022

	30 September 2022		
	Notes	£	£
Fixed Assets			
Participations in operating partnerships	2	_	188,000 188,000
Current assets			
Debtors		2,575	
Cash at bank and in hand		4,800	
Total current assets		7,375	
Creditors: amounts falling due within one year	r	(489)	
Net current assets			6,886
	•	_	
Net Assets		_	194,886
Capital and reserves			
Called up share capital			96,400
Share premium			96,400
Profit and Loss account		_	2,086
Shareholders' funds		=	194,886

- a. For the period ended 30 September 2022 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006.
- b. Members have not required the Company to obtain an audit in accordance with section 476 of the Companies Act
- c. The directors acknowledge their responsibility for:
- i) ensuring the Company keeps accounting records which comply with Section 386 and the Companies Act 2006, and
- ii) preparing accounts which give true and fair view of the state of affairs of the Company as at the end of the financial year, and of its profit and loss for the financial year, in accordance with the requirements of section 396 of the Companies Act 2006, and which otherwise comply with the requirements of the Companies Act relating to accounts, so far as is applicable to the Company.
- d. The accounts have been prepared in accordance with the provisions applicable to Companies subject to the small Companies' regime and in accordance with the provisions of FRS 102 Section 1A small entities.

Approved by the Board and authorised for issue on 28 April 2023.

And signed on their behalf by:

Edward Mole

On behalf of CTC Directorships Ltd

Director

Notes to the accounts For the period ended 30 September 2022

General Information

Brera Life Sciences Consultancy Trading Limited is a private company limited by shares, incorporated and domiciled in the United Kingdom. These financial statements are prepared for this entity only.

The address of its registered office is 338 Euston Road, London NW1 3BG

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest \mathfrak{L} .

The company has no employees.

1 Accounting policies

1.1 Basis of Preparation

The accounts are prepared under the historical cost convention as modified by the revaluation of certain assets where applicable, in accordance with the provisions of FRS 102 Section 1A - small entities.

The company has taken advantage of the exemption in FRS 102 Section 1A - small entities from the requirement to produce a cash flow statement.

These accounts have been prepared on a going concern basis.

1.2 Partnership Income and Losses

Partnership income and losses are shown on an accruals basis and represent the net income derived from the Company's participation in operating partnerships.

1.3 Participation in operating partnerships

Participation in operating partnerships are shown at cost (or where applicable modified by underlying valuations in the operating partnership's where values are obtained).

1.4 Tax

Tax is recognised in the statement of total comprehensive income. The current corporation tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

Participation in operating partnerships	Period to 30 September 2022 £
Participation in operating partnerships	188,000
Movement in the period	
01 October 2021	-
Additions	188,000
Disposals	· •
Revaluations	<u>-</u>
30 September 2022	188,000

3 Related party disclosures

E Mole, Director of the company is also an officer of Alpha Real Property Investment Advisers LLP (Alpha). Alpha administers the operating partnerships in which the company had an interest during the period. For this service Alpha receives fees as stated below:

1.5% on participations in operating partnerships.

4 Ultimate Controlling Party

The ultimate controlling party holding 100% of the share capital is: Brera Life Sciences Consultancy Limited